-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewSeizures – Drugs In Development, 2024
Empower your strategies with our Seizures – Drugs In Development, 2024 report and make more profitable business decisions. A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US...
-
Product Insights
NewMild Cognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol. The Mild...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewStatus Epilepticus – Drugs In Development, 2024
Empower your strategies with our Status Epilepticus – Drugs In Development, 2024 report and make more profitable business decisions. Status epilepticus is an emergency neurological condition where seizures last for more than five minutes; historically, it was diagnosed for seizures longer than than 30 minutes. Patients with this condition do not regain consciousness between seizures, which can lead to death. Hence, it requires immediate emergency evaluation and management. Seizures can be convulsive or non-convulsive, and are most commonly observed in pediatric...
-
Product Insights
NewTraumatic Brain Injury – Drugs In Development, 2024
Empower your strategies with our Traumatic Brain Injury – Drugs In Development, 2024 report and make more profitable business decisions. Traumatic brain injury (TBI) happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factors include age. Certain types of traumatic brain injury increase the risk of developing...
-
Company Profile
SciSparc Ltd – Company Profile
SciSparc Ltd (SciSparc), formerly Therapix Biosciences Ltd, is a clinical-stage biopharmaceutical company which focuses on the development of cannabinoid-based pharmaceuticals for the treatment of central nervous system disorders. SciSparc’s major product candidates include SCI-110, for the treatment of Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Alzheimer’s disease and agitation, SCI-210, for the treatment of Autism Spectrum Disorder (ASD) and epilepsy, and SCI-160, for the treatment of pain. The company conducts its clinical programs in collaboration with various pharma companies...
Add to Basket -
Product Insights
Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder – Drugs In Development, 2022, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape. Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that...
-
Product Insights
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive...
-
Product Insights
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...